{"job_id": "def0dde7-c148-4d35-b2f1-9f2d831e54f4", "brochure_id": "def0dde7-c148-4d35-b2f1-9f2d831e54f4", "brochure_name": "Diva Brochure_6 Feb (1) (2).pdf", "status": "completed", "results": [{"statement": "DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter, CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: The term \"difficult intravenous access\" (DIVA) is commonly used but not clearly defined.|Repeated attempts at peripheral intravenous catheter (PIVC) insertion can be a traumatic experience for patients, leading to sub-optimal clinical and economic outcomes.", "validation_result": "Supported", "page_location": "Abstract", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "DIVA: A Growing Challenge in the Asia Pacific Region. Difficult Intravenous Access (DIVA) refers to the challenge of securing IV access due to:", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: The term \"difficult intravenous access\" (DIVA) is used\nin the literature to describe this patient population, but\nthere is inconsistency in how DIVA is defined, and to our\nknowledge no systematic search has been undertaken to\nevaluate these definitions.", "validation_result": "Supported", "page_location": "Page 2, column 1, paragraph 1", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "For DIVA Patients, Every Stick Matters. Proactively identifying and managing DIVA patients can help:", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "For DIVA Patients, Every Stick Matters. Reduce complications", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: Peripheral IV catheter failures and related complications are costly to the health care system.", "validation_result": "Supported", "page_location": "Page 1, Costs of Peripheral IV Catheter Failure", "confidence_score": 0.7, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "MEDIUM"}, {"statement": "For DIVA Patients, Every Stick Matters. Higher insertion success rates", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: Peripheral IV catheter failures and related complications are costly to the health care system. | The average cost of a short peripheral IV catheter insertion in the United States is between $28 and $35 for straightforward \u201cfirst-stick\u201d insertions.", "validation_result": "Supported", "page_location": "Page 1, Costs of Peripheral IV Catheter Failure section", "confidence_score": 0.8, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "For DIVA Patients, Every Stick Matters. Reduce healthcare costs", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: Peripheral IV catheter failures and related complications are costly to the health care system.|The average cost of a short peripheral IV catheter insertion in the United States is between $28 and $35 for straightforward \"first-stick\u201d insertions.7,19 However, actual costs can vary considerably, depending on geographic and institutional factors, as well as the type of IV catheter inserted, and the type and extent of supportive technology employed (eg, dressing, needleless connector, extension tubing, dedicated stabilization device).7,19", "validation_result": "Supported", "page_location": "Page 1, Costs of Peripheral IV Catheter Failure section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "For DIVA Patients, Every Stick Matters. Preserve vein health", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: Costs of treating peripheral IV failure-related complications and their sequelae, such as bleeding, hematoma formation, infusate extravasation, thrombophlebitis, and catheter-related bloodstream infection (CR-BSI), are added to the basic costs of catheter removal and reinsertion.27-30 Caustic medication extravasation from a failed IV catheter can lead to extensive tissue necrosis and the need for repeated surgical debridement and reconstruction.29,31 It has been estimated that a single case of catheter-related bloodstream infection (CR-BSI) adds 7 to 20 days to hospital length of stay and up to $56 000 in additional cost, with total costs reaching as much as $2.3 billion in US intensive care units alone each year.15,16,32,33 The increase in multi-antibiotic-resistant \u201csuperbugs,\u201d such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus (VRE), and carbapenem-resistant Enterobacteriaceae (CRE), is particularly alarming and has created a real potential for simple peripheral IV catheter surface contamination to have lethal consequences in even otherwise healthy patients.34-37", "validation_result": "Supported", "page_location": "Page 2, Costs of Peripheral IV Catheter Failure section", "confidence_score": 0.8, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Keeping DIVA patients S.A.F.E.. The optimal DIVA management strategy involves screening all patients prior to any attempted vascular access device insertion.", "reference_no": "2", "reference": "Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189-203. doi:10.1097/NAN.0000000000000100.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 2.Helm RE, 2015.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "Throughout the document", "confidence_score": 0.1, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "DIVA: A Growing Challenge in the Asia Pacific Region. While nearly 90% of hospital inpatients need vascular access, DIVA affects over one-third of adults and up to 50% of children - often resulting in repeated, painful attempts.", "reference_no": "3", "reference": "Sou V, McManus C, Mifflin N, Frost SA, Ale J, Alexandrou E. A clinical pathway for the management of difficult venous access. BMC Nursing. 2017;16(1). doi:https://- doi.org/10.1186/s12912-017-0261-z.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 3.Sou2017.pdf: Over a third of adults and up to half of the children that present to hospital who require a PIVC, are reported to have difficult venous access (DiVA) [4, 5].", "validation_result": "Supported", "page_location": "Page 1, Background section, paragraph 2", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Understanding the Burden of DIVA. Increased patient pain", "reference_no": "3", "reference": "Sou V, McManus C, Mifflin N, Frost SA, Ale J, Alexandrou E. A clinical pathway for the management of difficult venous access. BMC Nursing. 2017;16(1). doi:https://- doi.org/10.1186/s12912-017-0261-z.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 3.Sou2017.pdf: Patients with DiVA may undergo multiple, painful at-tempts to gain peripheral venous access [7].|Many patients are admitted to hospital with non-visible or palpable veins, often resulting in multiple painful attempts at cannulation, anxiety and catheter failure.", "validation_result": "Supported", "page_location": "Page 1, Introduction | Page 1, Abstract", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. History of IV access for chemotherapy and other drugs", "reference_no": "1,3", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: A history of difficult IV access was also regularly associated with DIVA (six publications) [theme 3].\n- 3.Sou2017.pdf: Patients with chronic and complex disease, who have a history of intravenous drug use, are obese or malnourished or who have received chemotherapy, are cohorts known to suffer from DiVA [5\u20137].", "validation_result": "Supported", "page_location": "Page 3, paragraph 'Risk factors' | Page 1, Background section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. History of IV access for chemotherapy and other drugs", "reference_no": "1,3", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: A history of difficult IV access was also regularly associated with DIVA (six publications) [theme 3].\n- 3.Sou2017.pdf: Patients with chronic and complex disease, who have a history of intravenous drug use, are obese or malnourished or who have received chemotherapy, are cohorts known to suffer from DiVA [5\u20137].", "validation_result": "Supported", "page_location": "Page 3, paragraph 'Risk factors' | Page 1, Background section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. Non-visible or non-palpable veins", "reference_no": "1,3", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Of these, themes 1-3 (failed attempts at PIV access using traditional technique; based on physical examination findings for example no visible or palpable veins; and personal history of DIVA) were covered by all but one publication.|\"A patient is considered to have DIVA if any of the following elements are present: a clinician has two or more failed attempts at PIV access using traditional techniques, physical examination findings are suggestive of DIVA (e.g. no visible or palpable veins) or the patient has a stated or documented history of DIVA.\"\n- 3.Sou2017.pdf: Difficult venous access is characterised by non-visible and non-palpable veins where a highly experienced oper-ator is required with the use of technological aids to insert a vascular device [6].", "validation_result": "Supported", "page_location": "Page 1, Abstract | Page 5, Discussion | Page 1, Background section, paragraph 2", "confidence_score": 0.975, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. Non-visible or non-palpable veins", "reference_no": "1,3", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Of these, themes 1-3 (failed attempts at PIV access using traditional technique; based on physical examination findings for example no visible or palpable veins; and personal history of DIVA) were covered by all but one publication.|\"A patient is considered to have DIVA if any of the following elements are present: a clinician has two or more failed attempts at PIV access using traditional techniques, physical examination findings are suggestive of DIVA (e.g. no visible or palpable veins) or the patient has a stated or documented history of DIVA.\"\n- 3.Sou2017.pdf: Difficult venous access is characterised by non-visible and non-palpable veins where a highly experienced oper-ator is required with the use of technological aids to insert a vascular device [6].", "validation_result": "Supported", "page_location": "Page 1, Abstract | Page 5, Discussion | Page 1, Background section, paragraph 2", "confidence_score": 0.975, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. Chronic health conditions such as diabetes, obesity or malnutrition", "reference_no": "1,3", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Risk factors. The risk factors for DIVA reported across the publications align with the common themes reported for the definition of DIVA. Although there was great variability in the factors proposed, significant indicators included vein characteristics (palpability, visibility, poor vein condition, vein diameter, veins with many valves) (seven publications) [theme 2]; patient age (six publications); arthrometric values (patients classed as obese or underweight) (five publications); chronic health conditions (IV drug abuse, edema, cancer chemotherapy, diabetes, sickle cell disease, end-stage renal disease) (four publications) [theme 4]; gender (female) (four publications).\n- 3.Sou2017.pdf: Patients with chronic and complex disease, who have a history of intravenous drug use, are obese or malnourished or who have received chemotherapy, are cohorts known to suffer from DiVA [5\u20137].", "validation_result": "Supported", "page_location": "Page 3, paragraph starting with \"Risk factors.\" | Page 1, Background section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. Chronic health conditions such as diabetes, obesity or malnutrition", "reference_no": "1,3", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Risk factors. The risk factors for DIVA reported across the publications align with the common themes reported for the definition of DIVA. Although there was great variability in the factors proposed, significant indicators included vein characteristics (palpability, visibility, poor vein condition, vein diameter, veins with many valves) (seven publications) [theme 2]; patient age (six publications); arthrometric values (patients classed as obese or underweight) (five publications); chronic health conditions (IV drug abuse, edema, cancer chemotherapy, diabetes, sickle cell disease, end-stage renal disease) (four publications) [theme 4]; gender (female) (four publications).\n- 3.Sou2017.pdf: Patients with chronic and complex disease, who have a history of intravenous drug use, are obese or malnourished or who have received chemotherapy, are cohorts known to suffer from DiVA [5\u20137].", "validation_result": "Supported", "page_location": "Page 3, paragraph starting with \"Risk factors.\" | Page 1, Background section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Risk Factors. Patients with a history of DIVA are at almost 5x greater risk of experiencing this difficulty again.", "reference_no": "6", "reference": "Rodriguez-Calero MA, de Pedro-Gomez JE, Molero-Ballester LJ, et al. Risk Factors for Difficult Peripheral Intravenous Cannulation. The PIVV2 Multicentre Case-Control Study. Journal of Clinical Medicine. 2020;9(3):799. doi:https://doi.org/10.3390/-jcm9030799.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 6.Rodriguez,2020.pdf: This study identifies independent risk factors for difficulty in peripheral venous cannulation in patients treated in a hospital setting. A previous history of DPIVC, the presence of non-palpable veins, acute alterations in the upper limbs and the selection of the antecubital fossa for puncture are all predisposing factors for DPIVC. Patients with a previous history of DPIVC are at almost five times greater risk of experiencing this difficulty again.", "validation_result": "Supported", "page_location": "Page 20, Discussion section", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Understanding the Burden of DIVA. Increase in costs and inefficient use of resources", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: Ultimately, detrimental clinical outcomes can result in increased costs and inefficient use of resources.", "validation_result": "Supported", "page_location": "Introduction, end of paragraph 1", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Goals of Care in DIVA Patients. Prevent unnecessary escalation to more invasive products, delays in therapy and other complications.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Goals of Care in DIVA Patients. Reduce clinician stress and workflow inefficiencies by decreasing the number of vascular access attempts.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Goals of Care in DIVA Patients. Alleviate the substantial economic burden associated with DIVA.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Vascular Access Planning. Device selection should always be based on patient assessment and device indications.", "reference_no": "1", "reference": "Bahl A, Johnson S, Alsbrooks K, Mares A, Gala S, Hoerauf K. Defining difficult intravenous access (DIVA): A systematic review. The Journal of Vascular Access. 2021;0(0):112972982110596. doi:https://doi.org/10.1177/11297298211059648.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 1. Bahl A,2021.pdf: The inclusion of patient history in the definition highlights the importance of documenting the assessment and listening to patients when they say they have experience of difficult access.", "validation_result": "Supported", "page_location": "Page 5, Discussion section, paragraph 2", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Non-vesicant or non-irritant Osmolarity < 900 mOsm/L* (Peripheral recommended)", "reference_no": "11,12", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: In this regard, there is a wide consensus in the recent literature that vesicant drugs, solutions with low (<5) or high (>9) pH or very high osmolarity (>600mOsm/L), as well as any other solution with potential irritant effects on the vein wall by other mechanisms not involving pH or osmolarity, should be preferably delivered by a CVAD.|Solutions with osmolarity as high as 800-850 mOsm/L might be well tolerated by the endothelium, if they are delivered very slowly, for instance with a 24-h infusion, as it happens with parenteral nutrition.", "validation_result": "Supported", "page_location": "Page 5, Section 2 - Indications", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Non-vesicant or non-irritant Osmolarity < 900 mOsm/L* (Peripheral recommended)", "reference_no": "11,12", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: In this regard, there is a wide consensus in the recent literature that vesicant drugs, solutions with low (<5) or high (>9) pH or very high osmolarity (>600mOsm/L), as well as any other solution with potential irritant effects on the vein wall by other mechanisms not involving pH or osmolarity, should be preferably delivered by a CVAD.|Solutions with osmolarity as high as 800-850 mOsm/L might be well tolerated by the endothelium, if they are delivered very slowly, for instance with a 24-h infusion, as it happens with parenteral nutrition.", "validation_result": "Supported", "page_location": "Page 5, Section 2 - Indications", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Irritant or vesicant Osmolarity > 900 mOsm/L* (Central recommended)", "reference_no": "11,12", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: In this regard, there is a wide consensus in the recent literature that vesicant drugs, solutions with low (<5) or high (>9) pH or very high osmolarity (>600mOsm/L), as well as any other solution with potential irritant effects on the vein wall by other mechanisms not involving pH or osmolarity, should be preferably delivered by a CVAD.", "validation_result": "Supported", "page_location": "Page 5, Section 2 - Indications, Peripheral versus central venous access devices", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Irritant or vesicant Osmolarity > 900 mOsm/L* (Central recommended)", "reference_no": "11,12", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: In this regard, there is a wide consensus in the recent literature that vesicant drugs, solutions with low (<5) or high (>9) pH or very high osmolarity (>600mOsm/L), as well as any other solution with potential irritant effects on the vein wall by other mechanisms not involving pH or osmolarity, should be preferably delivered by a CVAD.", "validation_result": "Supported", "page_location": "Page 5, Section 2 - Indications, Peripheral versus central venous access devices", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Length of therapy", "reference_no": "11,12,13,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/4 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: The indications for specific PVADs are mainly based on the expected duration of treatment: SPC are appropriate for emergency and/or short duration access (24-48h); \"integrated\" SPC are appropriate for non-emergency access, when the expected duration is 2-7 days; LPC are appropriate in DIVA patients, or when expected duration is 1\u20134 weeks; MCs are appropriate when expected duration > 4 weeks.\n- 13. Pittiruti, M.pdf: Need for medium or long term i.v. line (months or years)|Needed for less than 4-6 weeks\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: The thematic blocks that made up this review were also raised by the members of the scientific committee, including aspects relating to the physiological implications of vascular access, the choice of venous capital for vascular access in oncology, the types of catheters available based on the duration of therapy, the procedures necessary for the cannulation of each of these catheters and the most relevant safety issues regarding the use of these devices in the cancer patient.", "validation_result": "Supported", "page_location": "Page 13, Table 1 | Page 6 and 7 | Page 4, Evidence review section", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 4 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Length of therapy", "reference_no": "11,12,13,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/4 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: The indications for specific PVADs are mainly based on the expected duration of treatment: SPC are appropriate for emergency and/or short duration access (24-48h); \"integrated\" SPC are appropriate for non-emergency access, when the expected duration is 2-7 days; LPC are appropriate in DIVA patients, or when expected duration is 1\u20134 weeks; MCs are appropriate when expected duration > 4 weeks.\n- 13. Pittiruti, M.pdf: Need for medium or long term i.v. line (months or years)|Needed for less than 4-6 weeks\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: The thematic blocks that made up this review were also raised by the members of the scientific committee, including aspects relating to the physiological implications of vascular access, the choice of venous capital for vascular access in oncology, the types of catheters available based on the duration of therapy, the procedures necessary for the cannulation of each of these catheters and the most relevant safety issues regarding the use of these devices in the cancer patient.", "validation_result": "Supported", "page_location": "Page 13, Table 1 | Page 6 and 7 | Page 4, Evidence review section", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 4 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Length of therapy", "reference_no": "11,12,13,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/4 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: The indications for specific PVADs are mainly based on the expected duration of treatment: SPC are appropriate for emergency and/or short duration access (24-48h); \"integrated\" SPC are appropriate for non-emergency access, when the expected duration is 2-7 days; LPC are appropriate in DIVA patients, or when expected duration is 1\u20134 weeks; MCs are appropriate when expected duration > 4 weeks.\n- 13. Pittiruti, M.pdf: Need for medium or long term i.v. line (months or years)|Needed for less than 4-6 weeks\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: The thematic blocks that made up this review were also raised by the members of the scientific committee, including aspects relating to the physiological implications of vascular access, the choice of venous capital for vascular access in oncology, the types of catheters available based on the duration of therapy, the procedures necessary for the cannulation of each of these catheters and the most relevant safety issues regarding the use of these devices in the cancer patient.", "validation_result": "Supported", "page_location": "Page 13, Table 1 | Page 6 and 7 | Page 4, Evidence review section", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 4 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Length of therapy", "reference_no": "11,12,13,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/4 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: The indications for specific PVADs are mainly based on the expected duration of treatment: SPC are appropriate for emergency and/or short duration access (24-48h); \"integrated\" SPC are appropriate for non-emergency access, when the expected duration is 2-7 days; LPC are appropriate in DIVA patients, or when expected duration is 1\u20134 weeks; MCs are appropriate when expected duration > 4 weeks.\n- 13. Pittiruti, M.pdf: Need for medium or long term i.v. line (months or years)|Needed for less than 4-6 weeks\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: The thematic blocks that made up this review were also raised by the members of the scientific committee, including aspects relating to the physiological implications of vascular access, the choice of venous capital for vascular access in oncology, the types of catheters available based on the duration of therapy, the procedures necessary for the cannulation of each of these catheters and the most relevant safety issues regarding the use of these devices in the cancer patient.", "validation_result": "Supported", "page_location": "Page 13, Table 1 | Page 6 and 7 | Page 4, Evidence review section", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 4 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Length of therapy", "reference_no": "11,12,13,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/4 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: The indications for specific PVADs are mainly based on the expected duration of treatment: SPC are appropriate for emergency and/or short duration access (24-48h); \"integrated\" SPC are appropriate for non-emergency access, when the expected duration is 2-7 days; LPC are appropriate in DIVA patients, or when expected duration is 1\u20134 weeks; MCs are appropriate when expected duration > 4 weeks.\n- 13. Pittiruti, M.pdf: Need for medium or long term i.v. line (months or years)|Needed for less than 4-6 weeks\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: The thematic blocks that made up this review were also raised by the members of the scientific committee, including aspects relating to the physiological implications of vascular access, the choice of venous capital for vascular access in oncology, the types of catheters available based on the duration of therapy, the procedures necessary for the cannulation of each of these catheters and the most relevant safety issues regarding the use of these devices in the cancer patient.", "validation_result": "Supported", "page_location": "Page 13, Table 1 | Page 6 and 7 | Page 4, Evidence review section", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 4 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Length of therapy", "reference_no": "11,12,13,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/4 support)", "matched_evidence": "- 12. Pittiruti, M.et Al. (2021_.pdf: The indications for specific PVADs are mainly based on the expected duration of treatment: SPC are appropriate for emergency and/or short duration access (24-48h); \"integrated\" SPC are appropriate for non-emergency access, when the expected duration is 2-7 days; LPC are appropriate in DIVA patients, or when expected duration is 1\u20134 weeks; MCs are appropriate when expected duration > 4 weeks.\n- 13. Pittiruti, M.pdf: Need for medium or long term i.v. line (months or years)|Needed for less than 4-6 weeks\n- 14.Magall\u00f3n-Pedrera,,2020.pdf: The thematic blocks that made up this review were also raised by the members of the scientific committee, including aspects relating to the physiological implications of vascular access, the choice of venous capital for vascular access in oncology, the types of catheters available based on the duration of therapy, the procedures necessary for the cannulation of each of these catheters and the most relevant safety issues regarding the use of these devices in the cancer patient.", "validation_result": "Supported", "page_location": "Page 13, Table 1 | Page 6 and 7 | Page 4, Evidence review section", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 4 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Venous assessment", "reference_no": "11,12,13", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 11.INS 2024.pdf: SECTION FIVE: \nVASCULAR ACCESS\nDEVICE SELECTION AND\nINSERTION\n- 12. Pittiruti, M.et Al. (2021_.pdf: Venous access devices (VADs) are defined as peripheral or central based on the position of the tip of the catheter.\n- 13. Pittiruti, M.pdf: The GAVeCeLT algorithm for choosing the most appropriate venous access device", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 4, Section I \u2013 Definition and classification | Title page", "confidence_score": 0.9333333333333332, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Venous assessment", "reference_no": "11,12,13", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 11.INS 2024.pdf: SECTION FIVE: \nVASCULAR ACCESS\nDEVICE SELECTION AND\nINSERTION\n- 12. Pittiruti, M.et Al. (2021_.pdf: Venous access devices (VADs) are defined as peripheral or central based on the position of the tip of the catheter.\n- 13. Pittiruti, M.pdf: The GAVeCeLT algorithm for choosing the most appropriate venous access device", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 4, Section I \u2013 Definition and classification | Title page", "confidence_score": 0.9333333333333332, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Venous assessment", "reference_no": "11,12,13", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 11.INS 2024.pdf: SECTION FIVE: \nVASCULAR ACCESS\nDEVICE SELECTION AND\nINSERTION\n- 12. Pittiruti, M.et Al. (2021_.pdf: Venous access devices (VADs) are defined as peripheral or central based on the position of the tip of the catheter.\n- 13. Pittiruti, M.pdf: The GAVeCeLT algorithm for choosing the most appropriate venous access device", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 4, Section I \u2013 Definition and classification | Title page", "confidence_score": 0.9333333333333332, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Long term", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: No direct quotes from paper (max 5 sentences, separated by | if multiple)", "validation_result": "Not Found", "page_location": "Throughout the document", "confidence_score": 0.05, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Access Device Selection Guide. Long term", "reference_no": "11", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 11.INS 2024.pdf: No direct quotes from paper (max 5 sentences, separated by | if multiple)", "validation_result": "Not Found", "page_location": "Throughout the document", "confidence_score": 0.05, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Access Device Selection Guide. < 7 days", "reference_no": "15", "reference": "Gonz\u00e1lez L\u00f3pez, J. L.et Al. (2014). Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. In Journal of Hospital Infection (Vol. 86, Issue 2, pp. 117\u2013126). doi.org/10.1016/j.jhin.2013.10.008.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 15. Gonz\u00e1lez L\u00f3pez 2014.pdf: I am sorry, but I could not find any information about \"< 7 days\" in the provided research paper.", "validation_result": "Not Found", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Access Device Selection Guide. Midline", "reference_no": "11,13", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: SECTION FIVE:\nVASCULAR ACCESS\nDEVICE SELECTION AND\nINSERTION\n- 13. Pittiruti, M.pdf: Catetere Midline | accesso periferico > 3 settimane | accesso periferico ad uso extraospedaliero", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 8, in the flow chart describing venous access options", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Midline", "reference_no": "11,13", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: SECTION FIVE:\nVASCULAR ACCESS\nDEVICE SELECTION AND\nINSERTION\n- 13. Pittiruti, M.pdf: Catetere Midline | accesso periferico > 3 settimane | accesso periferico ad uso extraospedaliero", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 8, in the flow chart describing venous access options", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. PICC", "reference_no": "14,16,17", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: Regarding the different devices available for venous access in oncology, the survey results revealed that the parties responsible for cannulating each of them vary substantially. Thus, the majority of respondents (87.2%) said that the Nursing Department is responsible for implanting the peripheral catheter, while for the placement of PICCs, the parties responsible are mostly (80.0%) the Anesthesia or Vascular Surgery Departments or Venous Access Unit, followed by the Nursing Department (65.8%).\n- 16.PowerPICC Catheter Technical Data Sheet. 2019..pdf: PowerPICCT\u2122 Catheter, Nursing\n- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: PowerPICC SOLOM 2 Catheter is a universal catheter\nsolution designed for IV (Intravenous) fluid and blood\nadministration and power injection.", "validation_result": "Supported", "page_location": "Page 7 | Top of the page | First paragraph", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. PICC", "reference_no": "14,16,17", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: Regarding the different devices available for venous access in oncology, the survey results revealed that the parties responsible for cannulating each of them vary substantially. Thus, the majority of respondents (87.2%) said that the Nursing Department is responsible for implanting the peripheral catheter, while for the placement of PICCs, the parties responsible are mostly (80.0%) the Anesthesia or Vascular Surgery Departments or Venous Access Unit, followed by the Nursing Department (65.8%).\n- 16.PowerPICC Catheter Technical Data Sheet. 2019..pdf: PowerPICCT\u2122 Catheter, Nursing\n- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: PowerPICC SOLOM 2 Catheter is a universal catheter\nsolution designed for IV (Intravenous) fluid and blood\nadministration and power injection.", "validation_result": "Supported", "page_location": "Page 7 | Top of the page | First paragraph", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. PICC", "reference_no": "14,16,17", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: Regarding the different devices available for venous access in oncology, the survey results revealed that the parties responsible for cannulating each of them vary substantially. Thus, the majority of respondents (87.2%) said that the Nursing Department is responsible for implanting the peripheral catheter, while for the placement of PICCs, the parties responsible are mostly (80.0%) the Anesthesia or Vascular Surgery Departments or Venous Access Unit, followed by the Nursing Department (65.8%).\n- 16.PowerPICC Catheter Technical Data Sheet. 2019..pdf: PowerPICCT\u2122 Catheter, Nursing\n- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: PowerPICC SOLOM 2 Catheter is a universal catheter\nsolution designed for IV (Intravenous) fluid and blood\nadministration and power injection.", "validation_result": "Supported", "page_location": "Page 7 | Top of the page | First paragraph", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. PICC", "reference_no": "14,16,17", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: Regarding the different devices available for venous access in oncology, the survey results revealed that the parties responsible for cannulating each of them vary substantially. Thus, the majority of respondents (87.2%) said that the Nursing Department is responsible for implanting the peripheral catheter, while for the placement of PICCs, the parties responsible are mostly (80.0%) the Anesthesia or Vascular Surgery Departments or Venous Access Unit, followed by the Nursing Department (65.8%).\n- 16.PowerPICC Catheter Technical Data Sheet. 2019..pdf: PowerPICCT\u2122 Catheter, Nursing\n- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: PowerPICC SOLOM 2 Catheter is a universal catheter\nsolution designed for IV (Intravenous) fluid and blood\nadministration and power injection.", "validation_result": "Supported", "page_location": "Page 7 | Top of the page | First paragraph", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. PICC", "reference_no": "14,16,17", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: Regarding the different devices available for venous access in oncology, the survey results revealed that the parties responsible for cannulating each of them vary substantially. Thus, the majority of respondents (87.2%) said that the Nursing Department is responsible for implanting the peripheral catheter, while for the placement of PICCs, the parties responsible are mostly (80.0%) the Anesthesia or Vascular Surgery Departments or Venous Access Unit, followed by the Nursing Department (65.8%).\n- 16.PowerPICC Catheter Technical Data Sheet. 2019..pdf: PowerPICCT\u2122 Catheter, Nursing\n- 17. PowerPICC Solo 2 catheter RN. Instruction For Use.2016.0741199 1602R.pdf: PowerPICC SOLOM 2 Catheter is a universal catheter\nsolution designed for IV (Intravenous) fluid and blood\nadministration and power injection.", "validation_result": "Supported", "page_location": "Page 7 | Top of the page | First paragraph", "confidence_score": 0.9166666666666666, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Midline", "reference_no": "11,13", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 11.INS 2024.pdf: SECTION FIVE:\nVASCULAR ACCESS\nDEVICE SELECTION AND\nINSERTION\n- 13. Pittiruti, M.pdf: Catetere Midline | accesso periferico > 3 settimane | accesso periferico ad uso extraospedaliero", "validation_result": "Supported", "page_location": "Page 5, Table of Contents | Page 8, in the flow chart describing venous access options", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. CICC", "reference_no": "14", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: ECO-SEOM-SEEO RECOMMENDATIONS FOR SAFE USE OF VENOUS ACCESSES IN\nCANCER PATIENTS|2. It is recommended that an appropriately approved intravenous oncology therapy\nmanagement protocol be established including the venous access device selection\nalgorithm recommended in this document, linked to the existing prescription systems for\nthis type of therapy at the center.", "validation_result": "Supported", "page_location": "Page 22, section \"ECO-SEOM-SEEO RECOMMENDATIONS FOR SAFE USE OF VENOUS ACCESSES IN CANCER PATIENTS\"", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Tunnelled CVC or Port", "reference_no": "11,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: To this end, although there is no clear definition of what should be considered short- or long-term, a recent study sets the limit at 30 days [7], which allows recommendations to be made to use PICCs for durations of implantation shorter than this period and tunneled catheters or PICCs for longer durations of implantation [11].|Generally speaking, they are divided into tunneled or non-tunneled catheters, the choice of which in each case will be determined mainly by the length of time they must remain implanted.", "validation_result": "Supported", "page_location": "Page 9: Central venous access catheters", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. CICC", "reference_no": "14", "reference": "Magall\u00f3n-Pedrera, I et Al. (2020). ECO-SEOM-SEEO safety recommendations guideline for cancer patients receiving intravenous therapy. In Clinical and Translational Oncology (Vol. 22, Issue 11, pp. 2049\u20132060). doi.org/10.1007/s12094-020-02347-1.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: ECO-SEOM-SEEO RECOMMENDATIONS FOR SAFE USE OF VENOUS ACCESSES IN\nCANCER PATIENTS|2. It is recommended that an appropriately approved intravenous oncology therapy\nmanagement protocol be established including the venous access device selection\nalgorithm recommended in this document, linked to the existing prescription systems for\nthis type of therapy at the center.", "validation_result": "Supported", "page_location": "Page 22, section \"ECO-SEOM-SEEO RECOMMENDATIONS FOR SAFE USE OF VENOUS ACCESSES IN CANCER PATIENTS\"", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Tunnelled CVC or Port", "reference_no": "11,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: To this end, although there is no clear definition of what should be considered short- or long-term, a recent study sets the limit at 30 days [7], which allows recommendations to be made to use PICCs for durations of implantation shorter than this period and tunneled catheters or PICCs for longer durations of implantation [11].|Generally speaking, they are divided into tunneled or non-tunneled catheters, the choice of which in each case will be determined mainly by the length of time they must remain implanted.", "validation_result": "Supported", "page_location": "Page 9: Central venous access catheters", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Access Device Selection Guide. Tunnelled CVC or Port", "reference_no": "11,14", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 14.Magall\u00f3n-Pedrera,,2020.pdf: To this end, although there is no clear definition of what should be considered short- or long-term, a recent study sets the limit at 30 days [7], which allows recommendations to be made to use PICCs for durations of implantation shorter than this period and tunneled catheters or PICCs for longer durations of implantation [11].|Generally speaking, they are divided into tunneled or non-tunneled catheters, the choice of which in each case will be determined mainly by the length of time they must remain implanted.", "validation_result": "Supported", "page_location": "Page 9: Central venous access catheters", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "PowerPICCT\u2122 Catheter. Provides efficient power injection.", "reference_no": "18", "reference": "BD PowerPICC: Instructions for Use (0735022).", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 18. 0735022 PowerPICC IFU.pdf: The PowerPICC* catheter is indicated for short or long term peripheral access to the central venous system for intravenous therapy, power injection of contrast media, and allows for central venous pressure monitoring.", "validation_result": "Supported", "page_location": "Page 2, Indications", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "PowerPICCT\u2122 Catheter. Offers versatility for multiple therapies and CVP monitoring.", "reference_no": "18", "reference": "BD PowerPICC: Instructions for Use (0735022).", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 18. 0735022 PowerPICC IFU.pdf: The PowerPICC* catheter is indicated for short or long term peripheral access to the central venous system for intravenous therapy, power injection of contrast media, and allows for central venous pressure monitoring.", "validation_result": "Supported", "page_location": "Page 2, Indications section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "PowerPICCT\u2122 Catheter. Designed to offer reliable vascular access.", "reference_no": "18", "reference": "BD PowerPICC: Instructions for Use (0735022).", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 18. 0735022 PowerPICC IFU.pdf: Catheters are packaged in a tray with accessories for reliable long (greater than 30 days) or short (less than 30 days) term vascular access.", "validation_result": "Supported", "page_location": "Page 2, Product Description", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD\u00ae PowerGlide Pro\u2122\u2122 Midline Catheter. Provides a dwell time of up to 30 days.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD\u00ae PowerGlide Pro\u2122\u2122 Midline Catheter. Allows access to deep veins by providing a long catheter.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD\u00ae PowerGlide Pro\u2122\u2122 Midline Catheter. Helps reduce multiple catheter insertions in patients with difficult intravenous access.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "Peripheral Venous Access. BD Instaflash\u2122\u2122\u2122 Needle Technology for improved first-stick success.", "reference_no": "19,20", "reference": "Seetharam AM, Raju U, Suresh K. A randomized controlled study to compare first stick success with Instaflash technology: The FIRSST study. JVA. 2022", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 19. Seetharam-et-al-2022-a-randomized-controlled-study-to-compare-first-stick-success-with-instaflash-technology-the-firsst.pdf: The present study evaluated performance efficacy of BD Venflon\u2122 | with Instaflash needle technology (investigational device) as compared to the BD Venflon\u2122\u2122 without Instaflash needle technology (control device).\n- 20. Van Loon 2022 The impact of a notched peripheral intravenous catheter.pdf: In the intervention group, a Venflon\u2122 Pro Safety catheter with the InstaFlash\u2122\u2122 Needle Technology (notched needle) was inserted, whereas patients in the control group received a Venflon\u2122\u2122 Pro Safety catheter without the InstaFlash\u2122\u2122 Needle Technology (non-notched needle).", "validation_result": "Supported", "page_location": "Abstract | Page 4, Procedure and intervention", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Peripheral Venous Access. BD Instaflash\u2122\u2122\u2122 Needle Technology for improved first-stick success.", "reference_no": "19,20", "reference": "Seetharam AM, Raju U, Suresh K. A randomized controlled study to compare first stick success with Instaflash technology: The FIRSST study. JVA. 2022", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 19. Seetharam-et-al-2022-a-randomized-controlled-study-to-compare-first-stick-success-with-instaflash-technology-the-firsst.pdf: The present study evaluated performance efficacy of BD Venflon\u2122 | with Instaflash needle technology (investigational device) as compared to the BD Venflon\u2122\u2122 without Instaflash needle technology (control device).\n- 20. Van Loon 2022 The impact of a notched peripheral intravenous catheter.pdf: In the intervention group, a Venflon\u2122 Pro Safety catheter with the InstaFlash\u2122\u2122 Needle Technology (notched needle) was inserted, whereas patients in the control group received a Venflon\u2122\u2122 Pro Safety catheter without the InstaFlash\u2122\u2122 Needle Technology (non-notched needle).", "validation_result": "Supported", "page_location": "Abstract | Page 4, Procedure and intervention", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "Peripheral Venous Access. Blood Control Technology to minimise blood exposure.", "reference_no": "22", "reference": "Onia R, Eshu-Wilson I, Arce C, et al. Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. CMRO. 2011;27(7):1339-1346.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 22. Onia R. REF-17281 (11) Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous bl.pdf: The central aim of this study was to evaluate a newly designed short PIVC (BD Insyte Autoguard* BC [Blood Control] Shielded IV Catheter), designed to specifically reduce exposure to blood related to the catheter insertion process.", "validation_result": "Supported", "page_location": "Page 2, Aim and hypothesis", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Peripheral Venous Access. Its safety features reduce needlestick injuries and blood leakage.", "reference_no": "22", "reference": "Onia R, Eshu-Wilson I, Arce C, et al. Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. CMRO. 2011;27(7):1339-1346.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 22. Onia R. REF-17281 (11) Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous bl.pdf: The design of the safety PIVC-BC reduces blood leakage, and consequently has the potential to reduce the risk of HCW blood exposure during IV catheter insertion, removal of the needle and up until the initial luer connection.", "validation_result": "Supported", "page_location": "Page 7, Conclusion", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. The BD Nexiva\u2122 Closed IV Catheter System is designed to enhance patient comfort by improving insertion success with BD Instaflash\u2122\u2122\u2122 Needle Technology, extending dwell times, and reducing catheter-related complications.", "reference_no": "15,19,20", "reference": "Gonz\u00e1lez L\u00f3pez, J. L.et Al. (2014). Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. In Journal of Hospital Infection (Vol. 86, Issue 2, pp. 117\u2013126). doi.org/10.1016/j.jhin.2013.10.008.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 15. Gonz\u00e1lez L\u00f3pez 2014.pdf: The COS PIVC (Figure 1) used in this study was the Nexiva closed intravenous catheter system with a Q-Syte luer access split-septum connector (BD, Franklin Lakes, NJ, USA).\n- 19. Seetharam-et-al-2022-a-randomized-controlled-study-to-compare-first-stick-success-with-instaflash-technology-the-firsst.pdf: The present study evaluated performance efficacy of BD Venflon\u2122 | with Instaflash needle technology (investigational device) as compared to the BD Venflon\u2122\u2122 without Instaflash needle technology (control device).\n- 20. Van Loon 2022 The impact of a notched peripheral intravenous catheter.pdf: In the intervention group, a Venflon\u2122 Pro Safety catheter with the InstaFlash\u2122\u2122 Needle Technology (notched needle) was inserted, whereas patients in the control group received a Venflon\u2122\u2122 Pro Safety catheter without the InstaFlash\u2122\u2122 Needle Technology (non-notched needle).", "validation_result": "Supported", "page_location": "Page 2, Materials section | Abstract | Page 4, Procedure and intervention", "confidence_score": 0.8333333333333334, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. The BD Nexiva\u2122 Closed IV Catheter System is designed to enhance patient comfort by improving insertion success with BD Instaflash\u2122\u2122\u2122 Needle Technology, extending dwell times, and reducing catheter-related complications.", "reference_no": "15,19,20", "reference": "Gonz\u00e1lez L\u00f3pez, J. L.et Al. (2014). Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. In Journal of Hospital Infection (Vol. 86, Issue 2, pp. 117\u2013126). doi.org/10.1016/j.jhin.2013.10.008.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 15. Gonz\u00e1lez L\u00f3pez 2014.pdf: The COS PIVC (Figure 1) used in this study was the Nexiva closed intravenous catheter system with a Q-Syte luer access split-septum connector (BD, Franklin Lakes, NJ, USA).\n- 19. Seetharam-et-al-2022-a-randomized-controlled-study-to-compare-first-stick-success-with-instaflash-technology-the-firsst.pdf: The present study evaluated performance efficacy of BD Venflon\u2122 | with Instaflash needle technology (investigational device) as compared to the BD Venflon\u2122\u2122 without Instaflash needle technology (control device).\n- 20. Van Loon 2022 The impact of a notched peripheral intravenous catheter.pdf: In the intervention group, a Venflon\u2122 Pro Safety catheter with the InstaFlash\u2122\u2122 Needle Technology (notched needle) was inserted, whereas patients in the control group received a Venflon\u2122\u2122 Pro Safety catheter without the InstaFlash\u2122\u2122 Needle Technology (non-notched needle).", "validation_result": "Supported", "page_location": "Page 2, Materials section | Abstract | Page 4, Procedure and intervention", "confidence_score": 0.8333333333333334, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. The BD Nexiva\u2122 Closed IV Catheter System is designed to enhance patient comfort by improving insertion success with BD Instaflash\u2122\u2122\u2122 Needle Technology, extending dwell times, and reducing catheter-related complications.", "reference_no": "15,19,20", "reference": "Gonz\u00e1lez L\u00f3pez, J. L.et Al. (2014). Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. In Journal of Hospital Infection (Vol. 86, Issue 2, pp. 117\u2013126). doi.org/10.1016/j.jhin.2013.10.008.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 15. Gonz\u00e1lez L\u00f3pez 2014.pdf: The COS PIVC (Figure 1) used in this study was the Nexiva closed intravenous catheter system with a Q-Syte luer access split-septum connector (BD, Franklin Lakes, NJ, USA).\n- 19. Seetharam-et-al-2022-a-randomized-controlled-study-to-compare-first-stick-success-with-instaflash-technology-the-firsst.pdf: The present study evaluated performance efficacy of BD Venflon\u2122 | with Instaflash needle technology (investigational device) as compared to the BD Venflon\u2122\u2122 without Instaflash needle technology (control device).\n- 20. Van Loon 2022 The impact of a notched peripheral intravenous catheter.pdf: In the intervention group, a Venflon\u2122 Pro Safety catheter with the InstaFlash\u2122\u2122 Needle Technology (notched needle) was inserted, whereas patients in the control group received a Venflon\u2122\u2122 Pro Safety catheter without the InstaFlash\u2122\u2122 Needle Technology (non-notched needle).", "validation_result": "Supported", "page_location": "Page 2, Materials section | Abstract | Page 4, Procedure and intervention", "confidence_score": 0.8333333333333334, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. It has a built-in stabilization platform that helps reduce the risk of securement-related complications.", "reference_no": "21", "reference": "Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabiliza- tion systems. J Infus Nurs. 2010;33(6):371-384.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: A closed catheter system (BD Nexiva Closed IV Catheter System, Becton, Dickinson and Company, Franklin Lakes, New Jersey) combines a PIV catheter with a built-in stabilization platform and a preattached extension tube exiting the hub at a 45-degree angle.", "validation_result": "Supported", "page_location": "Page 2, paragraph 4", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. Helps mitigate risks to healthcare providers by preventing needlestick injuries and blood exposure through its passive safety mechanism and closed integrated extension set.", "reference_no": "11,21", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: The investigational group catheter and stabilization pro-tocol included the insertion of a BD Nexiva Closed IV Catheter System with a built-in stabilization platform and extension tubing with 2 split-septum access ports (Figure 2).", "validation_result": "Supported", "page_location": "Page 4, Investigational Group section", "confidence_score": 0.8, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Nexiva\u2122\u2122 Closed IV Catheter System. Helps mitigate risks to healthcare providers by preventing needlestick injuries and blood exposure through its passive safety mechanism and closed integrated extension set.", "reference_no": "11,21", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: The investigational group catheter and stabilization pro-tocol included the insertion of a BD Nexiva Closed IV Catheter System with a built-in stabilization platform and extension tubing with 2 split-septum access ports (Figure 2).", "validation_result": "Supported", "page_location": "Page 4, Investigational Group section", "confidence_score": 0.8, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Venflon\u2122\u2122\u2122 Pro Safety Needle Protected IV Cannula. BD Vialon\u2122\u2122 catheter material is designed to enhance patient comfort by softening inthe vein, enabling longer dwell times.", "reference_no": "23,24", "reference": "Kus B, Buyukyilmaz F. Effectiveness of Vialon biomaterial versus Teflon catheters for peripheral intravenous placement: A randomized clinical trial. Jpn J Nurs Sci. 2020;e12328.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 23. Kus B. REF-15004 Kus, Effectiveness of vialon biomaterial versus teflon catheters, 2019.pdf: This study concluded that vialon biomaterial catheter (BD Insyte\u2122 Autoguard\u2122\u2122 BC winged) demonstrates longer dwell time of PIVC, lower phlebitis rate and phlebitis score than teflon catheter (BD VenflonTM).\n- 24. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral ....pdf: Although most peripheral intravenous catheters used in the United States at present are made of a Teflon, catheters made of polyurethanes are available. | A novel catheter material, polyetherurethane (PEU) (PEU-Vialon, Becton Dickinson, Franklin Lakes, New Jersey) is based on polytetramethylene ether glycol, 4,4'-diphenyl-methane diiosocyanate, and 1,4-butanediol. | It does not require catalysts or stabilizers in its manufacture, has a smoother microsurface, and is thermoplastic and more hydrophilic, becoming much more flexible than Teflon at body temperature.", "validation_result": "Supported", "page_location": "Abstract | Page 2, column 2", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Venflon\u2122\u2122\u2122 Pro Safety Needle Protected IV Cannula. BD Vialon\u2122\u2122 catheter material is designed to enhance patient comfort by softening inthe vein, enabling longer dwell times.", "reference_no": "23,24", "reference": "Kus B, Buyukyilmaz F. Effectiveness of Vialon biomaterial versus Teflon catheters for peripheral intravenous placement: A randomized clinical trial. Jpn J Nurs Sci. 2020;e12328.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 23. Kus B. REF-15004 Kus, Effectiveness of vialon biomaterial versus teflon catheters, 2019.pdf: This study concluded that vialon biomaterial catheter (BD Insyte\u2122 Autoguard\u2122\u2122 BC winged) demonstrates longer dwell time of PIVC, lower phlebitis rate and phlebitis score than teflon catheter (BD VenflonTM).\n- 24. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral ....pdf: Although most peripheral intravenous catheters used in the United States at present are made of a Teflon, catheters made of polyurethanes are available. | A novel catheter material, polyetherurethane (PEU) (PEU-Vialon, Becton Dickinson, Franklin Lakes, New Jersey) is based on polytetramethylene ether glycol, 4,4'-diphenyl-methane diiosocyanate, and 1,4-butanediol. | It does not require catalysts or stabilizers in its manufacture, has a smoother microsurface, and is thermoplastic and more hydrophilic, becoming much more flexible than Teflon at body temperature.", "validation_result": "Supported", "page_location": "Abstract | Page 2, column 2", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Insyte\u2122 Autoguard\u2122 BC Pro Shielded IV Catheter. Softening capabilities of the BD Vialon\u2122\u2122 Catheter material allows for longer dwell time and helps reduce phlebitis occurrence.", "reference_no": "23,24,25", "reference": "Kus B, Buyukyilmaz F. Effectiveness of Vialon biomaterial versus Teflon catheters for peripheral intravenous placement: A randomized clinical trial. Jpn J Nurs Sci. 2020;e12328.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 23. Kus B. REF-15004 Kus, Effectiveness of vialon biomaterial versus teflon catheters, 2019.pdf: This study concluded that vialon biomaterial catheter (BD Insyte\u2122 Autoguard\u2122\u2122 BC winged) demonstrates longer dwell time of PIVC, lower phlebitis rate and phlebitis score than teflon catheter (BD VenflonTM).|Vialon\u2122\u2122 biomaterial softens up to 70% in the vein, enabling longer dwell times and reducing the chance of mechanical phlebitis by up to 50% (Maki & Ringer, 1991).\n- 24. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral ....pdf: The use of peripheral intravenous catheters made of PEU-Vialon appears to pose the same risk for catheter-related infection as the use of catheters made of FEP-Teflon, and PEU-Vialon can permit longer cannulation with less risk for phlebitis.\n- 25. Gaukroger et al 1998.pdf: The results show that the nature of the cannula was the single most important factor in the incidence and severity of infusion thrombophlebitis, Vialon\u00ae cannulae being associated with a 46% lower incidence than the Teflon\u00ae type.", "validation_result": "Supported", "page_location": "Abstract, Page 8 | Page 2, Conclusions | Page 1, Summary", "confidence_score": 0.9333333333333332, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Insyte\u2122 Autoguard\u2122 BC Pro Shielded IV Catheter. Softening capabilities of the BD Vialon\u2122\u2122 Catheter material allows for longer dwell time and helps reduce phlebitis occurrence.", "reference_no": "23,24,25", "reference": "Kus B, Buyukyilmaz F. Effectiveness of Vialon biomaterial versus Teflon catheters for peripheral intravenous placement: A randomized clinical trial. Jpn J Nurs Sci. 2020;e12328.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 23. Kus B. REF-15004 Kus, Effectiveness of vialon biomaterial versus teflon catheters, 2019.pdf: This study concluded that vialon biomaterial catheter (BD Insyte\u2122 Autoguard\u2122\u2122 BC winged) demonstrates longer dwell time of PIVC, lower phlebitis rate and phlebitis score than teflon catheter (BD VenflonTM).|Vialon\u2122\u2122 biomaterial softens up to 70% in the vein, enabling longer dwell times and reducing the chance of mechanical phlebitis by up to 50% (Maki & Ringer, 1991).\n- 24. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral ....pdf: The use of peripheral intravenous catheters made of PEU-Vialon appears to pose the same risk for catheter-related infection as the use of catheters made of FEP-Teflon, and PEU-Vialon can permit longer cannulation with less risk for phlebitis.\n- 25. Gaukroger et al 1998.pdf: The results show that the nature of the cannula was the single most important factor in the incidence and severity of infusion thrombophlebitis, Vialon\u00ae cannulae being associated with a 46% lower incidence than the Teflon\u00ae type.", "validation_result": "Supported", "page_location": "Abstract, Page 8 | Page 2, Conclusions | Page 1, Summary", "confidence_score": 0.9333333333333332, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Insyte\u2122 Autoguard\u2122 BC Pro Shielded IV Catheter. Softening capabilities of the BD Vialon\u2122\u2122 Catheter material allows for longer dwell time and helps reduce phlebitis occurrence.", "reference_no": "23,24,25", "reference": "Kus B, Buyukyilmaz F. Effectiveness of Vialon biomaterial versus Teflon catheters for peripheral intravenous placement: A randomized clinical trial. Jpn J Nurs Sci. 2020;e12328.", "matched_paper": "Multiple PDFs (3/3 support)", "matched_evidence": "- 23. Kus B. REF-15004 Kus, Effectiveness of vialon biomaterial versus teflon catheters, 2019.pdf: This study concluded that vialon biomaterial catheter (BD Insyte\u2122 Autoguard\u2122\u2122 BC winged) demonstrates longer dwell time of PIVC, lower phlebitis rate and phlebitis score than teflon catheter (BD VenflonTM).|Vialon\u2122\u2122 biomaterial softens up to 70% in the vein, enabling longer dwell times and reducing the chance of mechanical phlebitis by up to 50% (Maki & Ringer, 1991).\n- 24. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral ....pdf: The use of peripheral intravenous catheters made of PEU-Vialon appears to pose the same risk for catheter-related infection as the use of catheters made of FEP-Teflon, and PEU-Vialon can permit longer cannulation with less risk for phlebitis.\n- 25. Gaukroger et al 1998.pdf: The results show that the nature of the cannula was the single most important factor in the incidence and severity of infusion thrombophlebitis, Vialon\u00ae cannulae being associated with a 46% lower incidence than the Teflon\u00ae type.", "validation_result": "Supported", "page_location": "Abstract, Page 8 | Page 2, Conclusions | Page 1, Summary", "confidence_score": 0.9333333333333332, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 3 sources", "confidence_band": "HIGH"}, {"statement": "BD Prevue II Vascular Access System. The BD Prevue II System is designed to enhance vascular access by providing ultrasound visualization, which may increase first-attempt success rate in patients, including those with DIVA.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD Prevue II Vascular Access System. Ultrasound visualization may improve accuracy and first stick access.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD Prevue II Vascular Access System. Cue needle tracking technology is designed to provide precise needle guidance.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "BD Prevue II Vascular Access System. Compatible with Cue-enabled devices, including PowerGlide Pro Midline Catheters and AccuCath Ace Intravascular Catheters.", "reference_no": "10", "reference": "BD- 148243 DIVA Customer Presentation.", "matched_paper": "None", "matched_evidence": "No matching reference PDF was found for the extraction: 10", "validation_result": "Reference Missing", "page_location": "N/A", "confidence_score": 0.0, "matching_method": "Reference Filter", "analysis_summary": "Validation skipped: Reference Missing", "confidence_band": "LOW"}, {"statement": "SiteRite \u00ae9 Ultrasound System. The SiteRite\u00ae 9 Ultrasound System is an all-in-one solution for vascular access device placement, compatible with the Sherlock 3CG + Tip Confirmation System (TCS) for catheter tip tracking.", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: The SiteRite\u2122 9 Ultrasound System is a portable device that features real-time 2D ultrasound imaging, customized vascular access applications, procedure documentation, vessel measurement tools, and electronic connectivity (if enabled).|The SiteRite\u2122 9 Ultrasound System is equipped with Cue\u2122 Needle Tracking System which is designed to track and display the location and trajectory of a needle under ultrasound guidance.|The SiteRite\u2122 9 Ultrasound System is compatible with the following accessories:\n\u2022\tSherlock 3CG+\u2122 Tip Confirmation System (TCS)", "validation_result": "Supported", "page_location": "Page 1, Section 2.1 | Page 1, Section 2.2 | Page 2, Section 2.8", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Vessel identification & measurement tools", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: The SiteRite\u2122\u2122\u2122 9 Ultrasound System is a portable device that features real-time 2D ultrasound imaging, customized vascular access applications, procedure documentation, vessel measurement tools, and electronic connectivity (if enabled).", "validation_result": "Supported", "page_location": "Page 5, Section 2.1 SiteRite\u2122 9 Ultrasound System device description", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Patient data lookup + & autofil|", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: Select Patient Queue to navigate to the Patient Queue screen. On this screen, enter patient information\nor access pre-entered patient information in the local queue.", "validation_result": "Supported", "page_location": "Page 13, Section 9.1.4 Patient Queue", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Ergonomic probe with button controls", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: SiteRite\u2122 9 Ultrasound System\nLinear 25 mm\nCue\u2122 Needle Tracking System Probe\nNote: The SiteRite 9\u2122 Ultrasound System Probe can be immersed in water or other liquids up to the button pad.", "validation_result": "Supported", "page_location": "Page 5, section 6.2 Compatible Probe", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Real-time needle tracking", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: The SiteRite\u2122 9 Ultrasound System is equipped with Cue\u2122 Needle Tracking System which is designed to track and display the location and trajectory of a needle under ultrasound guidance.", "validation_result": "Supported", "page_location": "Page 1, Section 2.2 Cue\u2122 Needle Tracking System description", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "SiteRite \u00ae9 Ultrasound System. Enhanced visuals on 15.6\" screen", "reference_no": "26", "reference": "BD SiteRite9 Ultrasound System: Instructions For Use (0756682)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 26. SiteRite9 IFU_SR9_0756682_en (1).pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.0, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "Sherlock 3CG+\u2122 + Surface Pro. For both adult and paediatric patients", "reference_no": "27", "reference": "BD Sherlock 3CG+ Tip Confirmation System for us with SiteRite9 Ultrasound System: Instructions For Use (0755866)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 27. Sherlock 3CG+\u2122 Tip Confirmation System For use with SiteRite\u2122 9 Ultrasound System IFU (2).pdf: In adult patients and in adolescents (greater than 12 through 21 years of age), the Sherlock 3CG+\u2122 TCS can be used with CVADS such as peripherally inserted central catheters (PICCs), central venous catheters (CVCs), implantable ports, and hemodialysis catheters. | In children (greater than 2 to 12 years of age), in infants (greater than 1 month to 2 years of age), and in neonates (from birth to 1 month of age), the Sherlock 3CG+\u2122 TCS can be used with PICCs and with centrally inserted central catheters (CICCs).", "validation_result": "Supported", "page_location": "Page 2, Section 1.1 Indications for Use", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Sherlock 3CG+\u2122 + Surface Pro. Using an identifiable P-wave", "reference_no": "27", "reference": "BD Sherlock 3CG+ Tip Confirmation System for us with SiteRite9 Ultrasound System: Instructions For Use (0755866)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 27. Sherlock 3CG+\u2122 Tip Confirmation System For use with SiteRite\u2122 9 Ultrasound System IFU (2).pdf: The Sherlock 3CG+\u2122 TCS displays an ECG signal detected by the intravascular and body electrodes, which can be used\nfor catheter tip positioning. | In patients with a distinct P-wave, the P-wave will increase in amplitude as the catheter\napproaches the top of the cavo-atrial junction.", "validation_result": "Supported", "page_location": "Page 3, Section 1.3.1 ECG Confirmation", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "Sherlock 3CG+\u2122 + Surface Pro. It offers an alternative method to chest X-ray fluoroscopy for CVAD tip placement, avoiding exposure to harmful radiation.", "reference_no": "27", "reference": "BD Sherlock 3CG+ Tip Confirmation System for us with SiteRite9 Ultrasound System: Instructions For Use (0755866)", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 27. Sherlock 3CG+\u2122 Tip Confirmation System For use with SiteRite\u2122 9 Ultrasound System IFU (2).pdf: The Sherlock 3CG+\u2122 Tip Confirmation System (TCS) is indicated for navigation and positioning of central venous access devices\n(CVADs) of at least 2 F in size. | The Sherlock 3CG+\u2122 TCS provides real-time catheter tip location information by using catheter\nnavigation technology along with the patient's cardiac electrical activity and is indicated for use as an alternative method to\nchest X-ray and fluoroscopy for CVAD tip placement confirmation of approaches from the superior vena cava.", "validation_result": "Supported", "page_location": "Page 2, Section 1.1 Indications for Use", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "ChloraPrep\u2122\u2122 Skin Preparation. BD ChloraPrep\u2122\u2122 is a skin antisepsis solution designed to optimise skin preparation and reduce infection risk. It features a single-use, non-touch applicator containing 2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA) in a sterile applicator.", "reference_no": "28", "reference": "Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980\u2013985.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 28. Ostrander 2005.pdf: Each lower extremity was prepared with one of three randomly selected solutions: DuraPrep (0.7% iodine and 74% isopropyl alcohol), Techni-Care (3.0% chloroxylenol), or ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol).", "validation_result": "Supported", "page_location": "Page 1, Methods section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "ChloraPrep\u2122\u2122 Skin Preparation. Effective antimicrobial action.", "reference_no": "28", "reference": "Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980\u2013985.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 28. Ostrander 2005.pdf: Conclusions: The use of effective preoperative preparation solution is an important step in limiting surgical wound contamination and preventing infection, particularly in foot and ankle surgery.|Of the three solutions tested in the present study, the combination of chlorhexidine and alcohol (ChloraPrep) was most effective for eliminating bacteria from the forefoot prior to surgery.", "validation_result": "Supported", "page_location": "Page 1, Conclusions section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "ChloraPrep\u2122\u2122 Skin Preparation. Can reduce colonisation of peripheral IV catheter tips by 60%.", "reference_no": "29", "reference": "Small H, Adams D, Casey A L, et al. Efficacy of adding 2% (w/v) chlorhexidine gluconate to 70% (v/v) isopropyl alcohol for skin disinfection prior to peripheral venous cannulation. Infect Control Hosp Epidemiol. 2008;29:963\u2013965.30. Madeo M, Barlow G. Reducing blood-culture contamination rates by the use of a 2% chlorhexidine solution applicator in acute admission units.JHosp Infect.2008;69:307\u2013309.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 29. Small et al. 200.pdf: Microorganisms were present on 39 (49.4%) of 79 PVC tips in the 70% IPA group, compared with 18 (19.8%) of 91 PVC tips in the 2% CHG in IPA group (P < .001; odds ratio, 4.0 [95% confidence interval, 2.0\u20137.8]).", "validation_result": "Supported", "page_location": "Page 3, Results section", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "ChloraPrep\u2122\u2122 Skin Preparation. Can decrease blood culture contamination rates by 72%.", "reference_no": "30", "reference": "", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 30. Madeo et al 2008.pdf: The proportion of blood cultures deemed to be contaminated decreased from 304/4072 (7.5%) prior to implementation (January to July 2007) to 40/1870 (2.1%) in the four months after implementation, excluding August as a 'washout' month (see Table I).", "validation_result": "Supported", "page_location": "Page 308, second column, second paragraph", "confidence_score": 0.85, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. The BD StatLock\u2122\u2122 Stabilization Device portfolio provides specialised solutions for arterial, epidural, dialysis, central venous, and peripheral IV catheters.", "reference_no": "31,32", "reference": "BD StatLock: Instructions for Use (35383).", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 31. StatLock IFU.pdf: StatLock* device is a stabilization device for compatible winged catheters.\n- 32. BD-142264 StatLock Stabilization Device Presentation.pdf: BD StatLock\u2122 PIVC\nStabilization Devices\nStatLock\u2122 PIVC Stabilization Devices are\nuniversally compatible with all BD peripheral\nIV catheters' - available in adult and pediatric\nsizes and shown to reduce IV therapy\ncomplications and the resulting unplanned\nIV restarts to improve patient care. 1|BD StatLock\u2122 Midline\nStabilization Devices\nStatLock\u2122 Pro Catheter Stabilization Devices\nare designed for the BD PowerGlide\u2122\nPro Midline Catheter Hub.|BD StatLock\u2122 PICC Plus\nStabilization Devices\nStatLock\u2122 PICC Stabilization Devices are a\n\"post and door\" design to house the suture\nwings of virtually all peripherally inserted\ncentral catheters (PICCs).|BD StatLock\u2122 CVC\nStabilization Devices\nStatLock\u2122 CVC Stabilization Devices are\ndesigned to help reduce sharp injuries to\nhealthcare workers when they are securing\ncentral line catheters, in comparison to\nsuture stabilization.|BD StatLock\u2122 Universal\nStabilization Devices\nStatLock\u2122 Universal Plus Stabilization\nDevices are used for percutaneous\ndrainage catheters.|BD StatLock\u2122 Arterial Plus\nStabilization Devices\nStatLock\u2122 Arterial Stabilization Devices offer\nboth a patented luer lock extension set\n(for universal compatibility with all arterial\ncatheters) and clamshell retainer for ease\nof use.|BD StatLock\u2122 Dialysis\nStabilization Devices\nStatLock\u2122 Dialysis Stabilization Devices\nare sutureless stabilization devices offering\na safer alternative to suture securement.|BD StatLock\u2122 Epidural\nStabilization Devices\nStatLock\u2122 Epidural Stabilization Devices provide\na range of epidural stabilization tailored to help\nprevent issues and designed to ensure\ncontinuous and effective anesthesia.", "validation_result": "Supported", "page_location": "Page 1, Indications for Use | Page 13", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. The BD StatLock\u2122\u2122 Stabilization Device portfolio provides specialised solutions for arterial, epidural, dialysis, central venous, and peripheral IV catheters.", "reference_no": "31,32", "reference": "BD StatLock: Instructions for Use (35383).", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 31. StatLock IFU.pdf: StatLock* device is a stabilization device for compatible winged catheters.\n- 32. BD-142264 StatLock Stabilization Device Presentation.pdf: BD StatLock\u2122 PIVC\nStabilization Devices\nStatLock\u2122 PIVC Stabilization Devices are\nuniversally compatible with all BD peripheral\nIV catheters' - available in adult and pediatric\nsizes and shown to reduce IV therapy\ncomplications and the resulting unplanned\nIV restarts to improve patient care. 1|BD StatLock\u2122 Midline\nStabilization Devices\nStatLock\u2122 Pro Catheter Stabilization Devices\nare designed for the BD PowerGlide\u2122\nPro Midline Catheter Hub.|BD StatLock\u2122 PICC Plus\nStabilization Devices\nStatLock\u2122 PICC Stabilization Devices are a\n\"post and door\" design to house the suture\nwings of virtually all peripherally inserted\ncentral catheters (PICCs).|BD StatLock\u2122 CVC\nStabilization Devices\nStatLock\u2122 CVC Stabilization Devices are\ndesigned to help reduce sharp injuries to\nhealthcare workers when they are securing\ncentral line catheters, in comparison to\nsuture stabilization.|BD StatLock\u2122 Universal\nStabilization Devices\nStatLock\u2122 Universal Plus Stabilization\nDevices are used for percutaneous\ndrainage catheters.|BD StatLock\u2122 Arterial Plus\nStabilization Devices\nStatLock\u2122 Arterial Stabilization Devices offer\nboth a patented luer lock extension set\n(for universal compatibility with all arterial\ncatheters) and clamshell retainer for ease\nof use.|BD StatLock\u2122 Dialysis\nStabilization Devices\nStatLock\u2122 Dialysis Stabilization Devices\nare sutureless stabilization devices offering\na safer alternative to suture securement.|BD StatLock\u2122 Epidural\nStabilization Devices\nStatLock\u2122 Epidural Stabilization Devices provide\na range of epidural stabilization tailored to help\nprevent issues and designed to ensure\ncontinuous and effective anesthesia.", "validation_result": "Supported", "page_location": "Page 1, Indications for Use | Page 13", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. Reduce needlestick risks", "reference_no": "33", "reference": "Schears GJ. Summary of product trials for 10, 164 patients: comparing an intravenous stabilizing device to tape. J Infus Nurs. 2006;29(4):225-31.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 33. REF-14260 Schears_Summary_of_Product_Trials_for_10_164_Patients_.9 (1).pdf: Newer catheter-stabilizing technologies can help to reduce patient complications, for an overall cost savings, and consequently reduce needlestick exposures for healthcare providers by reducing restarts and prolonging dwell times.", "validation_result": "Supported", "page_location": "Page 225, Abstract", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. Reduce complications", "reference_no": "21,33", "reference": "Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabiliza- tion systems. J Infus Nurs. 2010;33(6):371-384.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: Schears GJ. Summary of product trials for 10,164 patients: comparing an intravenous stabilizing device to tape. J Infus Nurs. 2006;29(4):225-231.|Schears\u00b2 reported a 76% decrease in unscheduled restarts and a decrease in phlebitis rates from 3.6% to 0.7% with StatLock device stabilization versus traditional stabilization.\u00b2\n- 33. REF-14260 Schears_Summary_of_Product_Trials_for_10_164_Patients_.9 (1).pdf: Pooled data from prospective product trials at 83 hospitals compared tape to a standard peripheral intravenous (PIV) securement method with a PIV-specific catheter-stabilizing device (StatLock).|A 67% reduction (P < .001) in total patient complications was observed in the stabilizing device group, as compared with the tape group.|Also, the need for unscheduled PIV restarts was reduced by 76% with the stabilizing device (P < .001).|Newer catheter-stabilizing technologies can help to reduce patient complications, for an overall cost savings, and consequently reduce needlestick exposures for healthcare providers by reducing restarts and prolonging dwell times.", "validation_result": "Supported", "page_location": "Page 2, Introduction | Page 225, Abstract", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. Reduce complications", "reference_no": "21,33", "reference": "Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabiliza- tion systems. J Infus Nurs. 2010;33(6):371-384.", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: Schears GJ. Summary of product trials for 10,164 patients: comparing an intravenous stabilizing device to tape. J Infus Nurs. 2006;29(4):225-231.|Schears\u00b2 reported a 76% decrease in unscheduled restarts and a decrease in phlebitis rates from 3.6% to 0.7% with StatLock device stabilization versus traditional stabilization.\u00b2\n- 33. REF-14260 Schears_Summary_of_Product_Trials_for_10_164_Patients_.9 (1).pdf: Pooled data from prospective product trials at 83 hospitals compared tape to a standard peripheral intravenous (PIV) securement method with a PIV-specific catheter-stabilizing device (StatLock).|A 67% reduction (P < .001) in total patient complications was observed in the stabilizing device group, as compared with the tape group.|Also, the need for unscheduled PIV restarts was reduced by 76% with the stabilizing device (P < .001).|Newer catheter-stabilizing technologies can help to reduce patient complications, for an overall cost savings, and consequently reduce needlestick exposures for healthcare providers by reducing restarts and prolonging dwell times.", "validation_result": "Supported", "page_location": "Page 2, Introduction | Page 225, Abstract", "confidence_score": 0.925, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD StatLock\u2122\u2122 Stabilization Devices. Enhance patient safety", "reference_no": "21", "reference": "Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabiliza- tion systems. J Infus Nurs. 2010;33(6):371-384.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 21. BD-1549 Bausone-Gazda D. A randomized controlled trial to compare the complications of 2.pdf: Inadequately secured PIV catheters can pose patient safety issues that contribute significantly to catheter-related complications.", "validation_result": "Supported", "page_location": "Page 9, Discussion section, paragraph 1", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. Intended for maintaining vascular access device patency, BD PosiFlush\u2122\u2122 SP is designed for use with peripheral intravenous catheters (PIVCs), central venous catheters (CVCs), peripherally inserted central catheters (PICCs), and implanted venous access ports.", "reference_no": "34,35", "reference": "BD PosiFlush SP: Instructions for Use (REF-64684)", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 34. REF-55071 BD PosiFlush XS IFU 500067397 Rev. 2022-12.pdf: - BD PosiFlush\u2122 XS Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implanted venous access ports.\n- 35. REF-64684 IFU PosiFlush SP 10000223600 rev 06.pdf: - BD PosiFlush\u2122 SP Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implanted venous access ports.", "validation_result": "Supported", "page_location": "Page 1, under INTENDED USE/INDICATIONS FOR USE | Page 2, English Section, Intended Use/Indications for Use", "confidence_score": 0.975, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. Intended for maintaining vascular access device patency, BD PosiFlush\u2122\u2122 SP is designed for use with peripheral intravenous catheters (PIVCs), central venous catheters (CVCs), peripherally inserted central catheters (PICCs), and implanted venous access ports.", "reference_no": "34,35", "reference": "BD PosiFlush SP: Instructions for Use (REF-64684)", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 34. REF-55071 BD PosiFlush XS IFU 500067397 Rev. 2022-12.pdf: - BD PosiFlush\u2122 XS Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implanted venous access ports.\n- 35. REF-64684 IFU PosiFlush SP 10000223600 rev 06.pdf: - BD PosiFlush\u2122 SP Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implanted venous access ports.", "validation_result": "Supported", "page_location": "Page 1, under INTENDED USE/INDICATIONS FOR USE | Page 2, English Section, Intended Use/Indications for Use", "confidence_score": 0.975, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. BD PosiFlush\u2122\u2122\u2122 XS syringe is intended to minimise contamination in a sterile field.", "reference_no": "11,36", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: May be used on sterile fields. Provided in sterile packaging.", "validation_result": "Supported", "page_location": "Page 14, BD PosiFlush\u2122\u2122 XS Normal Saline Prefilled Syringe description", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. BD PosiFlush\u2122\u2122\u2122 XS syringe is intended to minimise contamination in a sterile field.", "reference_no": "11,36", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: May be used on sterile fields. Provided in sterile packaging.", "validation_result": "Supported", "page_location": "Page 14, BD PosiFlush\u2122\u2122 XS Normal Saline Prefilled Syringe description", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. Sterile saline.", "reference_no": "36", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush\u2122\u2122 SP Saline Prefilled Syringe|BD PosiFlush\u2122\u2122 XS Normal Saline Prefilled Syringe", "validation_result": "Supported", "page_location": "Page 14, product description", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. A consistent 10 mL barrel diameter to help lower catheter damage risk.", "reference_no": "11,36", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush Pre-Filled Syringes have a consistent 10mL syringe barrel diameter which may help lower the risk of catheter damage due to injection pressure", "validation_result": "Supported", "page_location": "Page 12", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. A consistent 10 mL barrel diameter to help lower catheter damage risk.", "reference_no": "11,36", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush Pre-Filled Syringes have a consistent 10mL syringe barrel diameter which may help lower the risk of catheter damage due to injection pressure", "validation_result": "Supported", "page_location": "Page 12", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. Optimised design available in 3 mL, 5 mL, and 10 mL sizes.", "reference_no": "36", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush\u2122\u2122 SP Saline Prefilled Syringe|Available: 3 mL, 5 mL, 10mL|BD PosiFlush\u2122\u2122 XS Normal Saline Prefilled Syringe|Available: 3 mL, 5 mL, 10 mL", "validation_result": "Supported", "page_location": "Page 14", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. The stopper is designed to reduce blood reflux, thereby improving clinical efficiency and reducing complications during flushing procedures.", "reference_no": "36,37", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush\u2122\u2122 Prefilled Syringe stopper is designed to reduce the likelihood of syringe-induced catheter reflux\n- 37. Hadaway Lynn.pdf: Many devices designed to prevent blood reflux and thus improve catheter patency have entered the US health-care market.", "validation_result": "Supported", "page_location": "Page 12, under the 'Stopper' feature description | Page 1, right column, paragraph 3", "confidence_score": 0.8999999999999999, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 SP & XS Prefilled Saline Syringes. The stopper is designed to reduce blood reflux, thereby improving clinical efficiency and reducing complications during flushing procedures.", "reference_no": "36,37", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush\u2122\u2122 Prefilled Syringe stopper is designed to reduce the likelihood of syringe-induced catheter reflux\n- 37. Hadaway Lynn.pdf: Many devices designed to prevent blood reflux and thus improve catheter patency have entered the US health-care market.", "validation_result": "Supported", "page_location": "Page 12, under the 'Stopper' feature description | Page 1, right column, paragraph 3", "confidence_score": 0.8999999999999999, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD Q-Syte\u2122 Needle-free Connector. The split-septum design of the BD Q-Syte\u2122\u2122\u2122 Needle-free Connector minimises CRBSI risk when used as part of a CRBSI prevention bundle and is preferred over mechanical valves.", "reference_no": "41", "reference": "Centers for Disease Control and Prevention (CDC). O\u2019Grady NP, Alexander M, Burns LA, et al.; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 41. Guideline-BSI-H.pdf: [No evidence text provided]", "validation_result": "Not Found", "page_location": "", "confidence_score": 0.1, "matching_method": "Aggregated (Not Found)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "LOW"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. The BD PosiFlush\u2122 Heparin and Lock Flush Syringe is a prefilled syringe designed to support safe and effective catheter care.", "reference_no": "36,38", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: The BD PosiFlush\u2122\u2122 Prefilled Flush Syringe Difference|Commitment to quality and patient safety is at the center of everything we do...|because every flush syringe is injected into a patient's bloodstream\n- 38. REF-17199 PosiFlush HL IFU.pdf: BD PosiFlush\u2122\u2122 Heparin Lock Flush Syringes are intended for maintenance of patency of vascular access devices only.", "validation_result": "Supported", "page_location": "Page 5, describing the BD PosiFlush\u2122\u2122 Prefilled Flush Syringe Difference | Page 1, Indications and Usage", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. The BD PosiFlush\u2122 Heparin and Lock Flush Syringe is a prefilled syringe designed to support safe and effective catheter care.", "reference_no": "36,38", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: The BD PosiFlush\u2122\u2122 Prefilled Flush Syringe Difference|Commitment to quality and patient safety is at the center of everything we do...|because every flush syringe is injected into a patient's bloodstream\n- 38. REF-17199 PosiFlush HL IFU.pdf: BD PosiFlush\u2122\u2122 Heparin Lock Flush Syringes are intended for maintenance of patency of vascular access devices only.", "validation_result": "Supported", "page_location": "Page 5, describing the BD PosiFlush\u2122\u2122 Prefilled Flush Syringe Difference | Page 1, Indications and Usage", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Intended to maintain patency of vascular access devices only.", "reference_no": "36,38", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: Intended for maintenance of patency of vascular access devices only.\n- 38. REF-17199 PosiFlush HL IFU.pdf: BD PosiFlush\u2122\u2122 Heparin Lock Flush Syringes are intended for maintenance of patency of vascular access devices only.", "validation_result": "Supported", "page_location": "Page 14, under the description of BD PosiFlush\u2122\u2122 Heparin & Citrate Lock Flush Syringe | Page 1, Indications and Usage", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Intended to maintain patency of vascular access devices only.", "reference_no": "36,38", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (2/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: Intended for maintenance of patency of vascular access devices only.\n- 38. REF-17199 PosiFlush HL IFU.pdf: BD PosiFlush\u2122\u2122 Heparin Lock Flush Syringes are intended for maintenance of patency of vascular access devices only.", "validation_result": "Supported", "page_location": "Page 14, under the description of BD PosiFlush\u2122\u2122 Heparin & Citrate Lock Flush Syringe | Page 1, Indications and Usage", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Increases PIVC dwell time.", "reference_no": "36", "reference": "BD-92166 Posiflush Difference Customer Presentation", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: Increased catheter dwell time", "validation_result": "Supported", "page_location": "Page 11, under the heading \"Supported by 20+ clinical studies\"", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Consistent 10 mL barrel diameter to help lower catheter damage risk.", "reference_no": "11,36", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush Pre-Filled Syringes have a consistent 10mL syringe barrel diameter which may help lower the risk of catheter damage due to injection pressure", "validation_result": "Supported", "page_location": "Page 12", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD PosiFlush\u2122\u2122\u2122 Heparin and Lock Flush Syringe. Consistent 10 mL barrel diameter to help lower catheter damage risk.", "reference_no": "11,36", "reference": "Barbara J, et al. Infusion Therapy Standards of Practice, 9th Edition. J Infus Nurs. 2024;47(1S Suppl 1):S1-S285.12. Pittiruti, M.et Al. (2021). European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): AWoCoVA project. In The Journal of Vascular Access (Libk. 24, Issue 1, or. 165\u2013182) doi.org/10.1177/11297298211023274.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 36. PosiFlush Difference Customer Presentation [BD-92166].pdf: BD PosiFlush Pre-Filled Syringes have a consistent 10mL syringe barrel diameter which may help lower the risk of catheter damage due to injection pressure", "validation_result": "Supported", "page_location": "Page 12", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD MaxPlus\u2122\u2122 Needle-free Connector and BD MaxZero\u2122\u2122 Needle-free Connector. BD MaxPlus\u2122\u2122 and BD MaxZero\u2122\u2122 use the same needle-free connector technology, supported by a meta-analysis showing reduced CLABSI risk.", "reference_no": "39,40", "reference": "Tabak YP, Jarvis WR, Sun X, Crosby CT, Johannes RS. Meta-analysis on central line-associated bloodstream infections associated with a needleless intravenous connector with a new engineering design. Am J Infect Control. 2014;42(12):1278-1284.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 40. BD-66381 Needle-free Connectors Playbook FINAL 11.2022 (1).pdf: \u2022 BD MaxPlus\u2122 Needle-free Connector: Backed by a meta-analysis (one of the most rigorous levels of evidence in the scientific community) demonstrating reduced risk of CLABSI,2 supported with this FDA-cleared label statement*:|\u2022 BD MaxZero\u2122\u2122\u2122 Needle-free Connector: The same technology in a smaller size, with lower weight and reduced priming volume, making it appropriate for infants and children", "validation_result": "Supported", "page_location": "Page 8, Our NFC portfolio", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD MaxPlus\u2122\u2122 Needle-free Connector and BD MaxZero\u2122\u2122 Needle-free Connector. BD MaxPlus\u2122\u2122 and BD MaxZero\u2122\u2122 use the same needle-free connector technology, supported by a meta-analysis showing reduced CLABSI risk.", "reference_no": "39,40", "reference": "Tabak YP, Jarvis WR, Sun X, Crosby CT, Johannes RS. Meta-analysis on central line-associated bloodstream infections associated with a needleless intravenous connector with a new engineering design. Am J Infect Control. 2014;42(12):1278-1284.", "matched_paper": "Multiple PDFs (1/2 support)", "matched_evidence": "- 40. BD-66381 Needle-free Connectors Playbook FINAL 11.2022 (1).pdf: \u2022 BD MaxPlus\u2122 Needle-free Connector: Backed by a meta-analysis (one of the most rigorous levels of evidence in the scientific community) demonstrating reduced risk of CLABSI,2 supported with this FDA-cleared label statement*:|\u2022 BD MaxZero\u2122\u2122\u2122 Needle-free Connector: The same technology in a smaller size, with lower weight and reduced priming volume, making it appropriate for infants and children", "validation_result": "Supported", "page_location": "Page 8, Our NFC portfolio", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 2 sources", "confidence_band": "HIGH"}, {"statement": "BD MaxPlus\u2122\u2122 Needle-free Connector and BD MaxZero\u2122\u2122 Needle-free Connector. Uses positive displacement to expel fluid upon disconnection to help reduce occlusions.", "reference_no": "40", "reference": "BD-66381 Needle-free Connectors Playbook.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 40. BD-66381 Needle-free Connectors Playbook FINAL 11.2022 (1).pdf: Uses positive displacement to expel fluid upon disconnection to help reduce occlusions.", "validation_result": "Supported", "page_location": "Page 43, INSET 4.1 \u2013 'Why BD?' product RTBs (continued), item 10", "confidence_score": 0.9, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD MaxPlus\u2122\u2122 Needle-free Connector and BD MaxZero\u2122\u2122 Needle-free Connector. Features a proprietary flat surface that helps prevent contamination and bacterial entry when disinfected with a 3-second scrub using 70% IPA.", "reference_no": "40", "reference": "BD-66381 Needle-free Connectors Playbook.", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 40. BD-66381 Needle-free Connectors Playbook FINAL 11.2022 (1).pdf: The only technology\nwith a patented flat,\nsealed, solid surface\nthat helps prevent\ncontamination and\nbacteria from entering\nthe connector when\ndisinfected with a\n3-second scrub using\n70% IPA", "validation_result": "Supported", "page_location": "Page 37, Inset 3.3 \u2013 \u2018Why BD?' detail aids", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD Q-Syte\u2122 Needle-free Connector. Maximum flow rate of 32 L/hr enables diverse clinical applications.", "reference_no": "43", "reference": "BD Q-Syte Technical Data Sheet", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 43. BD Q-Syte TDS.pdf: BD Q-Syte\u2122 Luer Access Split Septum, stand- alone, non-sterile | 45 (310) | 32", "validation_result": "Supported", "page_location": "Page 1, Technical Information section", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. BD PureHub\u2122\u2122\u2122 Disinfecting Cap is designed to provide rapid disinfection and maintain a physical barrier against contamination.", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: BD PureHub\u2122\u2122\u2122 Disinfecting Cap demonstrated in-vitro, a 99.99% (>4 log) reduction on the most common causative agents in CRBSI including: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata, Candida albicans, Acinetobacter baumannii.*|Maintains a physical barrier to contamination for up to 7 days, if not removed++", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 0.95, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Disinfects with a sterilised 70% IPA solution.", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: BD PureHub\u2122\u2122\u2122 Disinfecting Cap demonstrated in-vitro, a 99.99% (>4 log) reduction on the most common causative agents in CRBSI including: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata, Candida albicans, Acinetobacter baumannii.*|Disinfects with a sterilized 70% isopropyl alcohol solution", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Rapid disinfection in 60 seconds.", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: BD PureHub\u2122 Disinfecting Cap demonstrated in-vitro, a 99.99% (>4 log) reduction on the most common causative agents in CRBSI including: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata, Candida albicans, Acinetobacter baumannii.*|Rapid disinfection in just 60seconds 27,28", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Provides 99.99% (>4 log) reduction in common pathogens.", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: BD PureHub\u2122 Disinfecting Cap demonstrated in-vitro, a 99.99% (>4 log) reduction on the most common causative agents in CRBSI including: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Candida glabrata, Candida albicans, Acinetobacter baumannii.*|Provides a > 4 log 99.99% reduction in bacteria 27, 28", "validation_result": "Supported", "page_location": "Page 15, under the heading \"BD PureHub\u2122 Disinfecting Cap\"", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}, {"statement": "BD PureHub\u2122\u2122\u2122 Disinfecting Cap. Maintains a physical barrier against contamination if not removed for up to 7 days.", "reference_no": "44", "reference": "BD-92271 Infection Prevention Clinical Compendium EMEA DIVA: Difficult Intravenous Access; IV: Intravenous; DVA: Difficult Venous Access; IVAD: Intravenous Access Difficulty; DPIVC: Difficult Peripheral Intravenous Cannulation; CECT: Contrast-Enhanced Computed Tomography; CVP: Central Venous Pressure; TCS: Tip Confirmation System; CVAD: Central Venous Access Device; CHG: Chlorhexidine Gluconate; IPA: Isopropyl Alcohol; PIVC: Peripheral Intravenous Catheter; CVC: Central Venous Catheter; PICC: Peripherally Inserted Central Catheter; CRBSI: Catheter-related Bloodstream Infections; CLABSI: Central Line-associated Bloodstream Infection; CICC: Centrally Inserted Central Catheter; ECG: Electrocardiogram", "matched_paper": "Multiple PDFs (1/1 support)", "matched_evidence": "- 44. BD-92271_Infection_Prevention_Clinical_Compendium_EMEA.pdf: Maintains a physical barrier against contamination for up to 7 days, if not removed++", "validation_result": "Supported", "page_location": "Page 15, under the image of the BD PureHub Disinfecting Cap", "confidence_score": 1.0, "matching_method": "Aggregated (Supported)", "analysis_summary": "Consolidated results from 1 sources", "confidence_band": "HIGH"}], "created_at": "2026-02-11T04:19:29.624465"}